Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK Plc

GSK Plc confirms 2024 guidance; Q3 dividend of 15p declared

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...
AstraZeneca

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...
GSK

FDA accepted New Drug Application for GSK’s Gepotidacin

GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025...
AstraZeneca

AstraZeneca’s Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

GSK

GSK Blenrep granted Breakthrough Therapy Designation by China’s CDE

GSK plc

GSK reports positive headline data from mRNA vaccine phase II trial

GSK plc

GSK HSV vaccine GSK3943104 did not meet primary efficacy objective

GSK plc

EMA approves expanded age indication for GSK’s RSV vaccine, Arexvy

GSK

GSK’s Nucala approved in Japan for treatment of CRSwNP

GSK

GSK plc to seek dismissal of upcoming Wilson case in Florida

GSK welcomes the Florida State Court's Daubert ruling excluding unreliable expert testimony, seeking dismissal of the Wilson case alleging ranitidine-prostate cancer link...
GSK

GSK wins jury verdict in Illinois ranitidine cancer case

GSK plc welcome favorable jury verdict in Illinois, ruling out any liability for plaintiff's colorectal cancer linked to ranitidine use...
AstraZeneca

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...
Aptamer Group

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...
GSK plc

GSK and CureVac to restructure collaboration into new licensing agreement

GSK plc and CureVac N.V. restructure their collaboration into a licensing agreement, enhancing mRNA vaccine development for influenza and COVID-19...
GSK

GSK’s Omjjara approved in Japan for treatment of myelofibrosis

GSK's Omjjara (momelotinib) gains approval from Japan's MHLW for treating myelofibrosis, addressing anaemia, symptoms, and splenomegaly in patients...
intravenous (IV) line

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...
Hikma Pharmaceuticals plc

Hikma enhances Injectables pipeline and manufacturing capabilities with Xellia acquisition

Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...
GSK

GSK starts appeal process of recent Delaware Daubert decision

GSK seeks appeal of recent Daubert ruling in Zantac litigation in Delaware Superior Court. Scientific consensus disputes claim of increased cancer risk...
GSK plc

GSK’s Arexvy RSV vaccine approved for adults 50-59 at risk of LRTD

GSK secures FDA approval for Arexvy in adults aged 50-59 at increased risk for RSV-LRTD. Clinical development ongoing, expanding vaccine benefits globally...
AstraZeneca

AstraZeneca completes acquisition of Fusion Pharmaceuticals

AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

GSK Plc

GSK Plc confirms 2024 guidance; Q3 dividend of 15p declared

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...
AstraZeneca

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...
GSK

FDA accepted New Drug Application for GSK’s Gepotidacin

GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025...
AstraZeneca

AstraZeneca’s Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

GSK

GSK Blenrep granted Breakthrough Therapy Designation by China’s CDE

GSK plc

GSK reports positive headline data from mRNA vaccine phase II trial

GSK plc

GSK HSV vaccine GSK3943104 did not meet primary efficacy objective

GSK plc

EMA approves expanded age indication for GSK’s RSV vaccine, Arexvy

GSK

GSK’s Nucala approved in Japan for treatment of CRSwNP

GSK

GSK plc to seek dismissal of upcoming Wilson case in Florida

GSK welcomes the Florida State Court's Daubert ruling excluding unreliable expert testimony, seeking dismissal of the Wilson case alleging ranitidine-prostate cancer link...
GSK

GSK wins jury verdict in Illinois ranitidine cancer case

GSK plc welcome favorable jury verdict in Illinois, ruling out any liability for plaintiff's colorectal cancer linked to ranitidine use...
AstraZeneca

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...
Aptamer Group

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...
GSK plc

GSK and CureVac to restructure collaboration into new licensing agreement

GSK plc and CureVac N.V. restructure their collaboration into a licensing agreement, enhancing mRNA vaccine development for influenza and COVID-19...
GSK

GSK’s Omjjara approved in Japan for treatment of myelofibrosis

GSK's Omjjara (momelotinib) gains approval from Japan's MHLW for treating myelofibrosis, addressing anaemia, symptoms, and splenomegaly in patients...
intravenous (IV) line

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...
Hikma Pharmaceuticals plc

Hikma enhances Injectables pipeline and manufacturing capabilities with Xellia acquisition

Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...
GSK

GSK starts appeal process of recent Delaware Daubert decision

GSK seeks appeal of recent Daubert ruling in Zantac litigation in Delaware Superior Court. Scientific consensus disputes claim of increased cancer risk...
GSK plc

GSK’s Arexvy RSV vaccine approved for adults 50-59 at risk of LRTD

GSK secures FDA approval for Arexvy in adults aged 50-59 at increased risk for RSV-LRTD. Clinical development ongoing, expanding vaccine benefits globally...
AstraZeneca

AstraZeneca completes acquisition of Fusion Pharmaceuticals

AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple